Efficacy and Tolerability of a Topical Formulation Containing Lactobacillaceae Strains in the Management of Chronic Dermatological Diseases
Dermatologic Therapy · 2026-01 · 2026 (1)
DOI: 10.1155/dth/1469442 ↗Kurz gefasst
Fachartikel in der Zeitschrift Dermatologic Therapy, online erschienen am 17.11.2026. Verfasst von Mario Puviani und 7 weiteren Autor:innen. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The human skin microbiome plays a pivotal role in the maintenance of cutaneous homeostasis by providing protection against invading pathogens and modulating local immune responses. Dysregulation in this microbial community can contribute to the onset and progression of chronic inflammatory skin conditions, such as eczema. While topical corticosteroids remain the first‐line treatment, given their anti‐inflammatory and immunosuppressive properties, their prolonged use poses limitations due to adverse effects. In this study, we evaluated the efficacy of a topical formulation containing three live Lactobacillaceae strains ( Lacticaseibacillus paracasei IMC 502, Lactiplantibacillus plantarum IMC 509, and Lacticaseibacillus rhamnosus SP 1) that have been studied for their probiotic properties, as an alternative topical approach to corticosteroid‐based formulations. Study Aim To evaluate the efficacy and tolerability of a Lactobacillaceae ‐containing topical formulation in the management of eczematous skin conditions. Subjects and Methods An 8‐week open‐label interventional study was conducted on 23 subjects presenting with signs of xerosis or inflammation. Participants were instructed to apply an oil‐based product containing L. paracasei IMC 502, L. plantarum IMC 509, and L. rhamnosus SP 1 to the affected skin areas twice daily for 8 weeks. Clinical and subjective evaluations of xerosis, erythema, desquamation, itching, burning sensation, and scratch marks were performed at baseline and after 4 and 8 weeks of treatment using a scale ranging from 0 to 4. Global clinical efficacy and subjective product tolerability were assessed at study completion.
Results
Clinical and subjective evaluations conducted after 4 and 8 weeks demonstrated statistically significant improvements across all evaluated parameters. At the end of the study, clinical and subjective xerosis scores decreased by 77% and 66%, respectively. Similarly, clinical and subjective erythema scores decreased by 74% and 75%, respectively. Clinical evaluation scores indicated a 73% reduction in desquamation and a 78% reduction in scratch marks, while subjective assessments revealed a 75% reduction in burning sensation and a 65% reduction in itching. No adverse events were reported throughout the study. The mean subjective tolerability score was 3.7, indicating a high level of product acceptability.
Conclusion
This study demonstrated the clinical efficacy, safety, and tolerability of a Lactobacillaceae ‐containing topical formulation for the management of eczematous skin conditions in adults.
Zitieren
APA
Puviani, M., Germoni, C., Calandra, P., Taverniti, V., Martínez, I., Verdenelli, M. C., Miorelli, L., & Marchetti, F. (2026). Efficacy and Tolerability of a Topical Formulation Containing Lactobacillaceae Strains in the Management of Chronic Dermatological Diseases. Dermatologic Therapy, 2026(1). https://doi.org/10.1155/dth/1469442
Vancouver
Puviani M, Germoni C, Calandra P, Taverniti V, Martínez I, Verdenelli MC, et al. Efficacy and Tolerability of a Topical Formulation Containing Lactobacillaceae Strains in the Management of Chronic Dermatological Diseases. Dermatologic Therapy. 2026;2026(1). doi:10.1155/dth/1469442
BibTeX
@article{Puviani2026,
author = {Puviani, Mario and Germoni, Chiara and Calandra, Paolo and Taverniti, Valentina and Martínez, Inés and Verdenelli, Maria Cristina and Miorelli, Lorenzo and Marchetti, Francesco},
title = {Efficacy and Tolerability of a Topical Formulation Containing Lactobacillaceae Strains in the Management of Chronic Dermatological Diseases},
journal = {Dermatologic Therapy},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/dth/1469442}
}
EUVIMED